Valerie Pierce - 02 Mar 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
SVP, GC & CCO
Signature
/s/ Valerie Pierce
Issuer symbol
NGM
Transactions as of
02 Mar 2023
Transactions value $
$0
Form type
4
Filing time
06 Mar 2023, 16:03:58
Previous filing
04 Mar 2022
Next filing
08 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Award $0 +49K +734.96% $0.00 55.7K 02 Mar 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +147K $0.00 147K 02 Mar 2023 Common Stock 147K $4.36 Direct F3
transaction NGM Stock Option (Right to Buy) Award $0 +150K $0.00 150K 02 Mar 2023 Common Stock 150K $4.36 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2 Includes 1,805 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on May 14, 2021 and 1,252 ESPP shares acquired on May 13, 2022.
F3 The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.
F4 1/2 of the shares subject to the stock option vest on the first anniversary of the grant date of March 2, 2023 (the "2023 Grant Date"), and the remaining 1/2 of the shares vest on the second anniversary of the 2023 Grant Date.